Message from RPS: COVID-19

Dear All,

Hope you and your teams are keeping well and staying safe.

Thank you for the calls and emails over the last couple of weeks. Your insights and inputs have and continue to be valuable. We have been submitting your asks to government and the NHS on an ongoing basis and trying ourselves to help with guidance via our hub page.

I am keen to still get more feedback from you to be able to lobby the government and national NHS teams on. I know calls on a regular basis are difficult, so please feel free to email your thoughts and suggestions to me directly when you can. My email is [email protected]

Thanks for all you and your teams for the fantastic work on the frontline.

Stay safe.

Ravi

Ravi Sharma | Director of England

Pharmacy and Member Experience

Royal Pharmaceutical Society

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article